GIGAGEN

pharmaceutical and therapeutic preparations for the treatment of immune deficiencies, autoimmune diseases, oncological diseases and disorders, infectious diseases, and organ, tissue, or cell transplant tolerance; therapeutic antibodies for the treatment of immune deficiencies, autoimmune diseases, oncological diseases and disorders, infectious diseases, and organ, tissue, or cell transplant tolerance

pharmaceutical drug discovery; research and development in the field of antibody-based therapies; research and development of pharmaceuticals in the fields of oncology, immunology, infectious diseases, and organ, tissue, or cell transplant tolerance; Scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics; scientific research in the nature of machine learning on single-cell data to identify and quantify cell type differences for the purpose of discovering novel targets; Medical and scientific research for the identification, preparation, and development of antibody libraries; DNA, protein, and antibody screening for scientific research purposes